3 ms·
Are drug manufacturers still spending more on marketing than on drug production? Don't they spend a good deal on simply trying to make a drug to work around so
by pbhjpbhj 7y ago
Are drug manufacturers still spending more on marketing than on drug production?
Don't they spend a good deal on simply trying to make a drug to work around someone else's IP, rather than making drugs where there is a new benefit -- that might account for most of the R&D for all I can tell, it doesn't appear to be included in this analysis?
- jandrewrogers 7y agoDrugs, like software, have very low production costs. The vast majority of the cost is in development. It is expected for marketing costs to exceed production costs while spending ordinary amounts on marketing as a consequence. Software companies spend far more on marketing than production costs for similar reasons. Marketing is essential for recovering development costs for drugs the same as it is for software. If marketing did not pay for itself and contribute positive revenue, nobody would do it. Drug companies have a finite amount of time to recover their very high development costs.
- monocasa 7y agoHe misspoke when he said production. He meant R&D. And yes, bug pharma spends more on marketing than R&D. https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/ https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-p...
- pbhjpbhj 7y agoYou're right, I didn't mean "manufacture". Production of a good to my understanding includes inter alia R&D and manufacture. All the steps from starting with nothing, to having goods to provide.
- aaavl2821 7y agoBig pharma companies spend a lot on marketing, often more than on r&d, but most drugs come from small companies with no marketing budget. These companies develop drugs, and partner with pharma to commercialize the drugs, or pharma buys them outright HBM did an analysis of novel FDA approved drugs from 2008-2018 which showed over 60% of FDA approved drugs were originally developed by small companies, and just 12% iirc by big pharma And most drug development efforts these days focus on medicines that can be truly impactful to patients. There is a correlation between clinical value and price, and many markets are winner take most, and winners are chosen by prescribers and payers based on their benefits to patients One data point to illustrate the industry's increased focus on innovation is that historically, nearly all drug development programs were small molecules and biologics -- decades-old tech. Of the companies that IPOd in the last 5 quarters, there are more gene and cell therapy programs than small molecule
- mft_ 7y ago> HBM did an analysis of novel FDA approved drugs from 2008-2018 Could you share the link to this article, please?
- aaavl2821 7y agohttp://www.hbmpartners.com/media/docs/industry-reports/Analysis-of-FDA-Approvals-2018-and-Previous-Years.pdf http://www.hbmpartners.com/media/docs/industry-reports/Analy...
- mft_ 7y ago> Are drug manufacturers still spending more on marketing than on drug production? Mostly, yes. (This data[1] is from 2015, but likely not too far off what's happening today.). > Don't they spend a good deal on simply trying to make a drug to work around someone else's IP, rather than making drugs where there is a new benefit -- that might account for most of the R&D for all I can tell, it doesn't appear to be included in this analysis? Honestly, not so much. The big money these days is in drugs which offer a transformational benefit over the current standard of care - whether that SoC is another marketed drug (either from the same company, or another) or a not very good treatment (or treatments) that no-one has improved upon yet. [1] https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/?utm_term=.f7f3cc15084a https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-p...